Citadel Advisors »

Aeglea Biotherapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2023-12-31 $12M 577k 21.52
2023-09-30 $1.2M 97k 12.25

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Microsoft Corporation Call Option (MSFT)
Meta Platforms Cl A Call Option (META)
Apple Call Option (AAPL)
Amazon Call Option (AMZN)
Ishares Tr Iboxx Hi Yd Etf Call Option (HYG)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Advanced Micro Devices Call Option (AMD)
Netflix Call Option (NFLX)
Alphabet Cap Stk Cl C Call Option (GOOG)
Booking Holdings Call Option (BKNG)

View all positions for Citadel Advisors

Top funds holding Aeglea Biotherapeutics

Perceptive Advisors
VR Adviser
Commodore Capital
venBio Select Advisor
Cormorant Asset Management
EcoR1 Capital
Franklin Resources
BVF
Wellington Management Company
Citadel Advisors
Braidwell
Global Endowment Management
First Turn Management
Fairmount Funds Management
Boxer Capital

View all funds holding Aeglea Biotherapeutics